Glaucoma News and Research

Latest Glaucoma News and Research

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

19 Mar 2010

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

StockPreacher.com announces an investment report featuring ACADIA Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 Mar 2010

OVD issue highlights prevalence of eye problems in general population

In the latest issue of Optometry & Vision Development (OVD), Dr. Dominick Maino, editor of OVD, notes that: "In 2010 there are 9 million people with lazy eye and 18 million individuals with eye-turns

17 Mar 2010

Promedior raises $12M in Series C financing

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.

16 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

QLT announces results from Phase II clinical trials and device study for PPDS

QLT Inc. today announced results from Phase II clinical trials and a device study for the punctal plug delivery system (PPDS). These studies are part of a development program that is being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. QLT also announced its plans to expand the program to evaluate a second drug for a new target indication.

11 Mar 2010

Lowering levels of Coonexin46 with use of siRNA will help prevent tumor formation

What began as research into how diabetics could possibly preserve their eyesight has led to findings that could prolong the vision of children afflicted with retinoblastoma.

10 Mar 2010

Aton Pharma introduces authorized generic version of Timoptic-XE

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE.

9 Mar 2010

Sunridge International to present patented, 2-minute, non-invasive PNT treatment at SWIA Conference

Sunridge International, said it will be presenting details of its patented pneumatic trabeculoplasty treatment a non-invasive treatment at the upcoming Southwest Investment Association, Inc. Conference on March 13, 2010, at the Westin Stonebriar Hotel in Frisco, Texas.

9 Mar 2010

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).

8 Mar 2010

Lexicon Pharmaceuticals proposes $95 million underwritten public offering of common stock

Lexicon Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to an additional $14,250,000 of common stock to cover over-allotments, if any.

8 Mar 2010

World through the eyes of a person with eye disease

Lighthouse International, the non-profit leader in vision healthcare, research, education and advocacy, launches a new website that features the first customizable, low-vision simulator that shows how a person with an eye disease sees the world. Visitors can choose a video from YouTube and select a filter that simulates retinitis pigmentosa, macular degeneration, glaucoma or diabetic retinopathy.

6 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Sunridge International, announced today that China's State Food and Drug Administration, (SFDA), had approved the firm's Pneumatic Trabeculoplasty (PNT) treatment in China.

3 Mar 2010

University of Michigan Health System opens new facility for eye care, diabetes research

On March 1, the first eye patients will enter an innovative new $132 million facility that expands the University of Michigan Health System's capacity for eye care, research and education, and unites diabetes researchers as they work to accelerate the search for a cure and prevention of diabetes.

27 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

Study: Elderly people with untreated visual disorders more likely to develop Alzheimer's disease

Elderly people with visual disorders that are left untreated are significantly more likely to develop Alzheimer's disease -- the most common form of dementia, according to a University of Michigan Health System study.

19 Feb 2010

Report: Green tea catechins may protect against glaucoma and other common eye diseases

Scientists have confirmed that the healthful substances found in green tea - renowned for their powerful antioxidant and disease-fighting properties - do penetrate into tissues of the eye. Their new report, the first documenting how the lens, retina, and other eye tissues absorb these substances, raises the possibility that green tea may protect against glaucoma and other common eye diseases.

19 Feb 2010

Glaucoma News and Research

Latest Glaucoma News and Research

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

OVD issue highlights prevalence of eye problems in general population

Promedior raises $12M in Series C financing

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

New MMMCC center improves patients’ access to medical marijuana

QLT announces results from Phase II clinical trials and device study for PPDS

Lowering levels of Coonexin46 with use of siRNA will help prevent tumor formation

Aton Pharma introduces authorized generic version of Timoptic-XE

Sunridge International to present patented, 2-minute, non-invasive PNT treatment at SWIA Conference

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

Lexicon Pharmaceuticals proposes $95 million underwritten public offering of common stock

World through the eyes of a person with eye disease

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

University of Michigan Health System opens new facility for eye care, diabetes research

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Study: Elderly people with untreated visual disorders more likely to develop Alzheimer's disease

Report: Green tea catechins may protect against glaucoma and other common eye diseases

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Glaucoma News and Research

Latest Glaucoma News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in